Related Experiment Videos
A DNA polymorphism at the alpha2-macroglobulin gene is associated with the severity of rheumatoid arthritis
I Zapico1, E Coto, A Rodríguez
1Servicio Reumatología and Genética Molecular, Instituto Reina Sofía de Investigacíon Nefrológica, Hospital Central de Asturias, Oviedo, Spain.
Objective:
To determine if DNA polymorphisms at the alpha2-macroglobulin (alpha2m) and angiotensin converting enzyme (ACE) genes were associated with rheumatoid arthritis (RA).
Methods:
A total of 160 patients (71 with early active severe RA, 89 with non-severe RA) were genotyped (polymerase chain reaction) for the alpha2m (5 bp deletion/insertion) and ACE (I/D) polymorphisms. We also genotyped 500 healthy controls from the same Caucasian population (Asturias, Northern Spain).
Results:
Carriers of the alpha2m deletion allele were at a significantly higher frequency among patients with an early active severe form of the disease, compared to patients with non-severe RA (p = 0.037). The frequency of the alpha2m deletion allele was significantly higher in patients with severe compared to nonsevere RA (p = 0.017). In addition, the frequency of the deletion allele was significantly higher among patients with 5 or more episodes of acute exacerbation of disease activity per year (n = 39) compared to those with none (n = 46) (p = 0.002). Gene and genotype frequencies for the ACE-I/D polymorphism did not differ between those with early active severe and non-severe RA.
Conclusion:
The genetic variation at alpha2m is associated with the severity of RA. Carriers of the alpha2m deletion allele would have increased risk of developing an early active severe form of the disease. Our data suggest that alpha2m could be a valuable target in the treatment of RA.
Insights
Genetic variations in alpha-2-macroglobulin (alpha2m) are linked to rheumatoid arthritis (RA) severity. The alpha2m deletion allele increases the risk of developing severe RA, suggesting alpha2m as a potential therapeutic target.
Area of Science:
- Genetics
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and potential joint destruction.
- Understanding the genetic factors influencing RA pathogenesis and severity is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the association between DNA polymorphisms in the alpha-2-macroglobulin (alpha2m) and angiotensin converting enzyme (ACE) genes and the clinical presentation of rheumatoid arthritis (RA).
Main Methods:
- Genotyping of 160 RA patients (71 early active severe, 89 non-severe) and 500 healthy controls for alpha2m (5 bp deletion/insertion) and ACE (I/D) polymorphisms using polymerase chain reaction.
- Statistical analysis to compare allele and genotype frequencies between patient subgroups and controls.
Main Results:
- The alpha2m deletion allele was found at a significantly higher frequency in patients with early active severe RA compared to those with non-severe RA (p = 0.037).
- A significant association was observed between the alpha2m deletion allele and increased disease severity, including a higher frequency of acute exacerbations (p = 0.002).
- No significant differences in gene or genotype frequencies for the ACE-I/D polymorphism were found between RA patient groups.
Conclusions:
- Genetic variation in the alpha2m gene is associated with the severity of rheumatoid arthritis.
- Carriers of the alpha2m deletion allele have an increased risk of developing an early active severe form of RA.
- The alpha2m gene represents a potential therapeutic target for managing RA severity.